Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease.
•Leptomeningeal disease occurs more commonly in BRCA-mutated ovarian cancer.•A clinically significant dose of olaprib is able to penetrate the leptomeninges.•Leptomeningeal metastases in a BRCA-mutated ovarian cancer responded to olaparib.
UCL Medical School, Gower St, London WC1E 6BT, UK.
Madeleine
M
Bangham
UCL Hospitals, 235 Euston Rd, Fitzrovia, London NW1 2BU, UK.
Robert
R
Goldstein
UCL Hospitals, 235 Euston Rd, Fitzrovia, London NW1 2BU, UK.
Henry
H
Walton
UCL Hospitals, 235 Euston Rd, Fitzrovia, London NW1 2BU, UK; UCL Cancer Institute, 90 Tottenham Court Road, London W1T 4TJ, UK.
Jonathan A
JA
Ledermann
BRCA mutation; Brain metastases; Leptomeningeal disease; Olaparib; Ovarian cancer; PARP inhibitor